Open AccessRespiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome
Author(s) -
Johnatas D. Silva,
Gisele P. Oliveira,
Cynthia S. Samary,
Carla Cristina de Araújo,
Gisele de A. Padilha,
Fernando Costa e Silva Filho,
Rosilane Taveira da Silva,
Marcelo EinickerLamas,
Marcelo M. Morales,
Vera Luíza Capelozzi,
Vanessa Martins da Silva,
Lı́dia Moreira Lima,
Eliezer J. Barreiro,
Bruno L. Diaz,
Paolo Pelosi,
Pedro Leme Silva,
Cristiane Souza Nascimento Baez Garcia,
Patrícia R. M. Rocco
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000443037
Subject(s) - pulmonary surfactant , ards , medicine , lung , sepsis , edema , respiratory distress , inflammation , pulmonary edema , diffuse alveolar damage , pharmacology , anesthesia , immunology , acute respiratory distress , chemistry , biochemistry
Exogenous surfactant has been proposed as adjunctive therapy for acute respiratory distress syndrome (ARDS), but it is inactivated by different factors present in the alveolar space. We hypothesized that co-administration of LASSBio596, a molecule with significant anti-inflammatory properties, and exogenous surfactant could reduce lung inflammation, thus enabling the surfactant to reduce edema and improve lung function, in experimental ARDS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom